Navigation Links
Neurochem announces departure of two members of management team
Date:2/21/2008

LAVAL, QC, Feb. 21 /PRNewswire-FirstCall/ - In light of Neurochem Inc.'s (NASDAQ: NRMX; TSX: NRM) new strategic direction, the Company announces the departure, effective February 21, 2008, of two members of its senior management team, Dr. Andreas Orfanos, MBB. Ch, MBA, Executive Vice President, Strategic Planning and Scientific Affairs, and Ms. Christine Lennon, MBA, Vice President, Business Development. The possibility of their acting as consultants in respect of specific projects is being explored.

"On behalf of the Board of Directors and my colleagues, I want to express our gratitude to Dr. Orfanos and Ms. Lennon for their dedication and valuable contribution to Neurochem. We wish them every success in the future," said Dr. Francesco Bellini, Neurochem's Chairman, President and CEO.

About Neurochem

Neurochem Inc. is a global health company focused on the research, development and commercialization of products to provide innovative health solutions to address critical unmet medical needs.

To Contact Neurochem

For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1-877-680-4500 or visit our Web Site at http://www.neurochem.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the Neurochem group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of Neurochem Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and Neurochem Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see the Annual Information Form of Neurochem Inc. for further risk factors that might affect the Neurochem group and its business.

Lise Hebert, PhD, Vice President, Corporate Communications, (450) 680-4572, lhebert@neurochem.com


'/>"/>
SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
2. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
3. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
4. Neurochem to present at JPMorgan Healthcare Conference
5. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
6. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
7. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
8. Neurochem reports results for third quarter of fiscal 2007
9. Emergency Dentist 24/7(TM) Announces Worldwide Licensing Program
10. LCA-Vision Announces Quarterly Dividend Payment
11. Cyberonics Reports Operating Profit for Third Quarter FY08 and Announces Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... August 22, 2017 , ... “Covert Awakening”: ... creation of published author, Julianne Hale, a consultant for the Intelligence Community. ... expert focusing on the Near East region. Julianne has written hundreds of ...
(Date:8/22/2017)... ... 2017 , ... Although Labor Day is not as popular for fireworks as ... displays, and numerous households celebrate the unofficial end of summer with backyard fireworks shows. ... , Kris Zambo, owner of Dynamite Fireworks in Hammond, Indiana, provides ...
(Date:8/21/2017)... ... 21, 2017 , ... FCPX LUT Monochromatic Volume 2 is an all-new Look-Up ... washed color grades to footage. A LUT is a Lookup Table that contains a ... corresponding color indicated by the table. This pack comes with 60 different monochromatic CUBE ...
(Date:8/21/2017)... ... , ... The experts have spoken. Prolonged sitting and standing are a no-no ... a healthy way these days? FlexiSpot, one of the fastest-growing manufacturers of ergonomic office ... introduce Deskcise Pro™– the world’s first sit-stand-cycle desk to backers worldwide. , The Launch ...
(Date:8/21/2017)... , ... August 21, 2017 , ... The Industrial ... Awards (IDSA IDEA®) 2017 Ceremony and Gala on Aug. 19, 2017 in Atlanta, ... of the world’s most prestigious and rigorous design competitions. See all the winners at ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)...  AOTI Inc. announced today that its fully owned ... a New York City Office in Yonkers, New York ... Wound Oxygen (TWO 2 ) homecare therapy. This new East Coast ... Care (ACHC) under the company,s DMEPOS accreditation for Home/Durable Medical Equipment ... Advanced Oxygen Therapy ...
(Date:8/11/2017)... CAESAREA, Israel , Aug. 11, 2017 ... company with mobile health and big data solutions, today ... results on Monday, August 14 and host a conference ... second quarter 2017 operating and financial results and its ... call will be hosted by Erez Raphael , ...
(Date:8/8/2017)...  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company ... results for the second quarter ended June 30, 2017. ... 2017 and to date: ... the Company,s lead project, BL-8040: Announced ... as novel stem cell mobilization treatment for autologous bone-marrow ...
Breaking Medicine Technology: